{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T03:48:12Z","timestamp":1761709692123},"reference-count":15,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2020,4,1]]},"DOI":"10.1001\/jamaoncol.2019.6390","type":"journal-article","created":{"date-parts":[[2020,1,30]],"date-time":"2020-01-30T16:31:08Z","timestamp":1580401868000},"page":"542","source":"Crossref","is-referenced-by-count":9,"title":["Expenditures for First- and Second-Generation Tyrosine Kinase Inhibitors Before and After Transition of Imatinib to Generic Status"],"prefix":"10.1001","volume":"6","author":[{"given":"Kelly M.","family":"Kenzik","sequence":"first","affiliation":[{"name":"Institute for Cancer Outcomes and Survivorship, University of Alabama at Birmingham, Birmingham"},{"name":"Division of Hematology and Oncology, University of Alabama at Birmingham, Birmingham"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ravi","family":"Bhatia","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, University of Alabama at Birmingham, Birmingham"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Smita","family":"Bhatia","sequence":"additional","affiliation":[{"name":"Institute for Cancer Outcomes and Survivorship, University of Alabama at Birmingham, Birmingham"},{"name":"Division of Pediatric Oncology, University of Alabama at Birmingham, Birmingham"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","reference":[{"issue":"5","key":"cbr190013r1","doi-asserted-by":"publisher","first-page":"e186","DOI":"10.1016\/S2352-3026(15)00048-4","article-title":"Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials.","volume":"2","author":"Sasaki","year":"2015","journal-title":"Lancet Haematol"},{"issue":"3","key":"cbr190013r2","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.japh.2017.01.004","article-title":"Medication adherence, molecular monitoring, and clinical outcomes in patients with chronic myelogenous leukemia in a large HMO.","volume":"57","author":"Haque","year":"2017","journal-title":"J Am Pharm Assoc"},{"issue":"3","key":"cbr190013r3","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1200\/JCO.2016.68.2914","article-title":"Long-term follow-up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia.","volume":"35","author":"Etienne","year":"2017","journal-title":"J Clin Oncol"},{"issue":"7","key":"cbr190013r5","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw003","article-title":"Cost-effectiveness of tyrosine kinase inhibitor treatment strategies for chronic myeloid leukemia in chronic phase after generic entry of imatinib in the United States.","volume":"108","author":"Padula","year":"2016","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"cbr190013r7","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1377\/hlthaff.2017.1684","article-title":"Generic price competition for specialty drugs: too little, too late?","volume":"37","author":"Cole","year":"2018","journal-title":"Health Aff (Millwood)"},{"issue":"2","key":"cbr190013r8","doi-asserted-by":"publisher","first-page":"93","DOI":"10.5639\/gabij","article-title":"The impact of pharmaceutical pricing and reimbursement policies on generics uptake: implementation of policy options on generics in 29 European countries\u2014an overview.","volume":"1","author":"Vogler","year":"2012","journal-title":"GaBI"},{"issue":"3","key":"cbr190013r9","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s40258-016-0300-z","article-title":"How can pricing and reimbursement policies improve affordable access to medicines? lessons learned from European countries.","volume":"15","author":"Vogler","year":"2017","journal-title":"Appl Health Econ Health Policy"},{"issue":"11","key":"cbr190013r10","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1002\/hec.3796","article-title":"The effects of state-level pharmacist regulations on generic substitution of prescription drugs.","volume":"27","author":"Song","year":"2018","journal-title":"Health Econ"},{"issue":"7","key":"cbr190013r11","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1377\/hlthaff.2009.0424","article-title":"State generic substitution laws can lower drug outlays under Medicaid.","volume":"29","author":"Shrank","year":"2010","journal-title":"Health Aff (Millwood)"},{"issue":"3","key":"cbr190013r13","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1377\/hlthaff.24.3.780","article-title":"Medicaid cost containment and access to prescription drugs.","volume":"24","author":"Cunningham","year":"2005","journal-title":"Health Aff (Millwood)"},{"issue":"11","key":"cbr190013r14","doi-asserted-by":"publisher","first-page":"e163","DOI":"10.1016\/j.clml.2015.07.647","article-title":"Economic burden of tyrosine kinase inhibitor treatment failure in chronic myeloid leukemia.","volume":"15","author":"Knopf","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"2","key":"cbr190013r15","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1002\/cncr.v124.2","article-title":"Adherence to tyrosine kinase inhibitors among Medicare Part D beneficiaries with chronic myeloid leukemia.","volume":"124","author":"Shen","year":"2018","journal-title":"Cancer"},{"key":"cbr190013r4","unstructured":"Truven Health Analytics. Red book, a comprehensive, consistent drug pricing resource. https:\/\/www.ibm.com\/watson-health\/learn\/truven-health-analytics. Accessed June 1, 2019."},{"key":"cbr190013r6","unstructured":"Health Resources and Service Administration. Consumer Price Index: Medical Care. US Department of Health and Human Services. https:\/\/www.hrsa.gov\/get-health-care\/affordable\/hill-burton\/cpi.html. Accessed September 17, 2019."},{"key":"cbr190013r12","unstructured":"Center for Medicare and Medicaid Services. Medicaid Drug Spending Dashboard. 2019; https:\/\/www.cms.gov\/Research-Statistics-Data-and-Systems\/Statistics-Trends-and-Reports\/Information-on-Prescription-Drugs\/Medicaid. Accessed September 17, 2019."}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2759195\/jamaoncology_kenzik_2020_br_190013.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,9]],"date-time":"2020-04-09T15:14:39Z","timestamp":1586445279000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2759195"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,1]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2019.6390","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4,1]]}}}